Inhibrx Inks Potential $500M Antibody License with Celgene
Just two years after its launch, privately held Inhibrx LLC hooked Celgene Corp. in its first antibody license. The deal for the undisclosed target potentially could exceed $500 million, including up-front, clinical and regulatory milestone payments and royalties on commercial sales.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST